VincentWooMD

Adult Congenital Heart Disease, Interventional Cardiology

Physician

Dr. Woo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4309 W Medical Center Dr
Ste A200
Mchenry, IL 60050
Phone+1 815-759-8070

Fax+1 815-759-4931

Loyola University Medical CenterFellowship, Cardiovascular Disease, 2012 - 2015
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 2009 - 2012
Saint Louis University School of MedicineClass of 2009

PubMed

22 citations
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults.
G B John Mancini, Eileen O'Meara, Shelley Zieroth, Mathieu Bernier, Alice Y Y Cheng
The Canadian Journal of Cardiology. 2022-08-01
3 citations
Fibrous Cap Thickness Predicts Stable Coronary Plaque Progression: Early Clinical Validation of a Semiautomated OCT Technology.
Nicholas Kassis, Tomas Kovarnik, Zhi Chen, Joseph R Weber, Brendan Martin
Journal of the Society for Cardiovascular Angiography & Interventions. 2022-07-13
3 citations
A Rare Case of RYR2 Mutation Causing Sudden Cardiac Arrest Due to Catecholaminergic Polymorphic Ventricular Tachycardia.
Lalitha Padmanabha Vemireddy, Ammar Aqeel, Grace W Ying, Delaram Majlesi, Vincent Woo
Cureus. 2021-02-18

Type 2 Diabetes and Cardiovascular Disease PreventionNovember 2nd, 2018
INVOKANA® (Canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction, and Stroke in the CANVAS ProgramJune 12th, 2017